Bolt Biotherapeutics Acquires Prana Therapies

Investor Group Provides $120 Million Private Placement to Bolt Biotherapeutics

October 24, 2026

Biotechnology

Bolt Biotherapeutics secured a concurrent $120 million private placement from Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital, and YK Bioventures. The financing is intended to fund Bolt’s operations into 2028 and advance PRA-216 and other pipeline programs; warrants could provide an additional $60 million.

Zymeworks Acquires Theravance Biopharma

June 29, 2026

Biotechnology

Zymeworks agreed to acquire all outstanding equity of Theravance Biopharma for $17 per share in cash, representing an announced transaction value of approximately $929 million. Theravance shareholders are also entitled to a contingent value right covering 80% of net proceeds from any future monetization of ampreloxetine; Zymeworks completed the acquisition on September 23, 2026.

Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline

June 18, 2026

Healthcare Services

Biogen entered into a definitive agreement to acquire RayThera, a private immunology-focused biotechnology company, for total consideration of up to $1 billion driven by an upfront payment plus clinical and regulatory milestone payments. The deal is expected to close in the third quarter of 2026, with Biogen taking over development, manufacturing, and global commercialization of RayThera’s small-molecule anti-inflammatory assets.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

ICON plc Acquires PRA Health Sciences in $12 Billion Deal

February 24, 2021

Healthcare Services

ICON plc entered into a definitive agreement to acquire PRA Health Sciences for approximately $12 billion in a cash-and-stock transaction. The deal combines ICON’s clinical research outsourcing platform with PRA’s mobile/connected health and real-world data capabilities to expand decentralized and hybrid trial solutions.

Kinaxis Acquires Prana Consulting to Establish India Services Hub

February 26, 2020

Consulting

Kinaxis Inc. has acquired Prana Consulting, a supply-chain consultancy based in India, to create a new services hub and add experienced RapidResponse practitioners. The acquisition expands Kinaxis's global services capacity and enhances its ability to support customers across automotive, high-tech, consumer packaged goods, life sciences and aerospace sectors.